Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
Steven S. Storage, Harsh Agrawal, Daniel E. Furst
Korean J Intern Med. 2010;25(1):1-17. Published online 2010 Feb 26 DOI: https://doi.org/10.3904/kjim.2010.25.1.1
Citations to this article as recorded by 
Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study
Ji Hyeon Ju, Yoon-Kyoung Sung, Joo-young Jo, Ja-Young Jeon, Hyun-Jeong Yoo, Eun Bong Lee
Modern Rheumatology.2023; 33(6): 1087. CrossRef
Quality of life and disease activity of patients with rheumatoid arthritis on tofacitinib and biologic disease-modifying antirheumatic drug therapies
Vladimira Boyadzhieva, Konstantin Tachkov, Nikolay Stoilov, Konstantin Mitov, Rumen Stoilov, Guenka Petrova
Rheumatology International.2022; 42(10): 1775. CrossRef
Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials
Yanrong Huang, Yong Fan, Yang Liu, Wenhui Xie, Zhuoli Zhang
Clinical Rheumatology.2019; 38(10): 2765. CrossRef
Adverse Cutaneous Reactions of Common Biologic Medications for Rheumatic Diseases
Urmi Khanna, Ariana M. Ellis, Anthony P. Fernandez
Current Treatment Options in Rheumatology.2019; 5(4): 290. CrossRef
Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
Sumit Kunwar, Christopher E. Collins, Florina Constantinescu
Clinical Rheumatology.2018; 37(10): 2611. CrossRef
Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis
Kyeong Min Son, Sung Yeon Lee, Young Il Seo, Ji-Eun Choi, Hyun Ah Kim
Clinical Rheumatology.2017; 36(6): 1221. CrossRef
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Susan M. Goodman, Bryan Springer, Gordon Guyatt, Matthew P. Abdel, Vinod Dasa, Michael George, Ora Gewurz‐Singer, Jon T. Giles, Beverly Johnson, Steve Lee, Lisa A. Mandl, Michael A. Mont, Peter Sculco, Scott Sporer, Louis Stryker, Marat Turgunbaev, Barry
Arthritis & Rheumatology.2017; 69(8): 1538. CrossRef
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Susan M. Goodman, Bryan Springer, Gordon Guyatt, Matthew P. Abdel, Vinod Dasa, Michael George, Ora Gewurz-Singer, Jon T. Giles, Beverly Johnson, Steve Lee, Lisa A. Mandl, Michael A. Mont, Peter Sculco, Scott Sporer, Louis Stryker, Marat Turgunbaev, Barry
The Journal of Arthroplasty.2017; 32(9): 2628. CrossRef
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Susan M. Goodman, Bryan Springer, Gordon Guyatt, Matthew P. Abdel, Vinod Dasa, Michael George, Ora Gewurz‐Singer, Jon T. Giles, Beverly Johnson, Steve Lee, Lisa A. Mandl, Michael A. Mont, Peter Sculco, Scott Sporer, Louis Stryker, Marat Turgunbaev, Barry
Arthritis Care & Research.2017; 69(8): 1111. CrossRef
Comparison of the disease activity score using the erythrocyte sedimentation rate and C‐reactive protein levels in Koreans with rheumatoid arthritis
Kyeong Min Son, Suk Yeon Kim, Sun Ho Lee, Chung Mi Yang, Young Il Seo, Hyun Ah Kim
International Journal of Rheumatic Diseases.2016; 19(12): 1278. CrossRef
Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
Sumit Kunwar, Khagendra Dahal, Sharan Sharma
Rheumatology International.2016; 36(8): 1065. CrossRef
Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials
Sumit Kunwar, Ashok Raj Devkota, Dipesh K. C. Ghimire
Rheumatology International.2016; 36(8): 1077. CrossRef
Infecções graves em pacientes com artrite reumatoide em uso de anakinra, rituximab ou abatacept: revisão sistemática de estudos observacionais
Vanderlea Poeys Cabral, Carlos Augusto Ferreira de Andrade, Sonia Regina Lambert Passos, Maria de Fátima Moreira Martins, Yara Hahr Marques Hökerberg
Revista Brasileira de Reumatologia.2016; 56(6): 543. CrossRef
Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies
Vanderlea Poeys Cabral, Carlos Augusto Ferreira de Andrade, Sonia Regina Lambert Passos, Maria de Fátima Moreira Martins, Yara Hahr Marques Hökerberg
Revista Brasileira de Reumatologia (English Edition).2016; 56(6): 543. CrossRef
Adverse effects of golimumab in the treatment of rheumatologic diseases
Hong Yang, Arthur Kavanaugh
Expert Opinion on Drug Safety.2014; 13(1): 103. CrossRef
Unexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in Humans
Nancy E. Everds, Jacqueline M. Tarrant
Toxicologic Pathology.2013; 41(2): 280. CrossRef
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
Mark C Genovese, Patrick Durez, Hanno B Richards, Jerzy Supronik, Eva Dokoupilova, Vadim Mazurov, Jacob A Aelion, Sang-Heon Lee, Christine E Codding, Herbert Kellner, Takashi Ikawa, Sophie Hugot, Shephard Mpofu
Annals of the Rheumatic Diseases.2013; 72(6): 863. CrossRef
Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T‐cell costimulation
M. Konsta, E. Rallis, A. Karameris, A. Stratigos, P.P. Sfikakis, A. Iliopoulos
Journal of the European Academy of Dermatology and Venereology.2012; 26(2): 257. CrossRef
Éruption paradoxale psoriasiforme induite par l’abatacept (ORENCIA®)
J.-L. Schmutz, P. Trechot
Annales de Dermatologie et de Vénéréologie.2012; 139(12): 871. CrossRef
Biologic Agents in Rheumatic Diseases
Myong Joo Hong, Wan-Hee Yoo
Korean Journal of Medicine.2012; 82(5): 549. CrossRef
Safe Use of Antirheumatic Agents in Patients with Comorbidities
Ashima Makol, Kerry Wright, Eric L. Matteson
Rheumatic Disease Clinics of North America.2012; 38(4): 771. CrossRef
Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets
Peter J Bugelski, Pauline L Martin
British Journal of Pharmacology.2012; 166(3): 823. CrossRef
Recent Paradigm Shifts in the Diagnosis and Treatment of Rheumatoid Arthritis
Young Ok Jung, Hyun Ah Kim
The Korean Journal of Internal Medicine.2012; 27(4): 378. CrossRef
Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis
Masaaki Hiura, Shintaro Abe, Akinari Tabaru, Shohei Shimajiri, Kentaro Hanami, Kazuyoshi Saito, Yoshiya Tanaka, Masaru Harada
Hepatology Research.2011; 41(5): 492. CrossRef
Tuberculosis and other infections in the anti-tumour necrosis factor-alpha (anti-TNF-α) era
Francesca Nacci, Marco Matucci-Cerinic
Best Practice & Research Clinical Rheumatology.2011; 25(3): 375. CrossRef
Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review
A. V. Hadjinicolaou, M. K. Nisar, S. Bhagat, H. Parfrey, E. R. Chilvers, A. J. K. Ostor
Rheumatology.2011; 50(12): 2297. CrossRef